News list for "5579.33"

On September 22nd, Yabao Pharmaceutical announced that the company decided to terminate the clinical research and development of SY-009 and make a full provision for asset impairment according to accounting standards. SY-009 is a sodium-glucose cotransporter 1 inhibitor, which is intended for the treatment of type 2 diabetes patients. As of the announcement date, the R & D investment of SY-009 totaled 87.8698 million yuan, of which the expensed amount was 32.0765 million yuan and the capitalized...

2025-09-22 08:06:27